Media Report Clarification

Lumosa Announces Details of Upcoming Institutional Investor Conference

Lumosa and Center Lab to Hold Joint Investor Press Conference for Material Announcement on 24/11/29

Center Lab Group Executive Takes Helm as New Lumosa Chairman to Drive Global Licensing of LT3001 Stroke Candidate

Clinical Enrollment on Track, Data Readout Expected by Year-End

Lumosa’s Lead Candidate LT3001 for Acute Ischemic Stroke Approaching Key Milestone, Targeting Unblinding in Late 2024

Lumosa Partner, AMed Co., Informed the Receipt of Market Authorization from Brunei (BDMCA), for Naldebain, an Extended-Release Analgesic Injection